JonesTrading Reiterates Hold Rating for Day One Biopharmaceuticals (NASDAQ:DAWN)

Day One Biopharmaceuticals (NASDAQ:DAWN)‘s stock had its “hold” rating reaffirmed by stock analysts at JonesTrading in a research note issued to investors on Friday,Benzinga reports. They presently have a $21.50 target price on the stock, up from their prior target price of $20.00. JonesTrading’s price target points to a potential upside of 1.37% from the stock’s previous close.

Other equities analysts have also issued reports about the company. JPMorgan Chase & Co. increased their price target on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research note on Monday, December 29th. Needham & Company LLC reiterated a “hold” rating on shares of Day One Biopharmaceuticals in a research report on Friday. HC Wainwright decreased their price target on shares of Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating for the company in a research note on Wednesday, February 25th. Finally, Oppenheimer restated a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Friday. Five investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $25.56.

Day One Biopharmaceuticals Trading Up 66.0%

Shares of Day One Biopharmaceuticals stock traded up $8.43 on Friday, reaching $21.21. The stock had a trading volume of 76,023,164 shares, compared to its average volume of 4,312,633. The business’s 50 day moving average is $10.87 and its two-hundred day moving average is $8.95. Day One Biopharmaceuticals has a 1 year low of $5.64 and a 1 year high of $21.23. The company has a market cap of $2.19 billion, a P/E ratio of -20.59 and a beta of -1.25.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its earnings results on Tuesday, February 24th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.04). The firm had revenue of $53.72 million during the quarter, compared to analysts’ expectations of $49.81 million. Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%. On average, equities analysts anticipate that Day One Biopharmaceuticals will post -0.72 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Lauren Merendino sold 5,814 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $67,442.40. Following the sale, the insider owned 60,157 shares of the company’s stock, valued at $697,821.20. This trade represents a 8.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Michael Vasconcelles sold 2,728 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $31,644.80. Following the completion of the sale, the insider owned 4,397 shares of the company’s stock, valued at $51,005.20. This represents a 38.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 36,461 shares of company stock worth $422,948 in the last three months. 6.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. Invesco Ltd. increased its position in Day One Biopharmaceuticals by 26.5% in the fourth quarter. Invesco Ltd. now owns 123,994 shares of the company’s stock worth $1,156,000 after buying an additional 25,952 shares in the last quarter. Oracle Investment Management Inc. bought a new position in shares of Day One Biopharmaceuticals during the 4th quarter valued at approximately $932,000. XTX Topco Ltd increased its holdings in Day One Biopharmaceuticals by 62.9% in the 4th quarter. XTX Topco Ltd now owns 128,440 shares of the company’s stock worth $1,197,000 after acquiring an additional 49,592 shares in the last quarter. VARCOV Co. bought a new stake in Day One Biopharmaceuticals during the 4th quarter worth approximately $261,000. Finally, Vestal Point Capital LP raised its stake in Day One Biopharmaceuticals by 94.4% during the 4th quarter. Vestal Point Capital LP now owns 5,200,000 shares of the company’s stock worth $48,464,000 after acquiring an additional 2,525,000 shares during the period. Institutional investors own 87.95% of the company’s stock.

More Day One Biopharmaceuticals News

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Servier agreed to acquire Day One for $21.50 per share in cash, implying a total equity value of ~ $2.5B; transaction expected to close in Q2 subject to customary conditions — a clear liquidity event and floor price for shareholders. Read More.
• Positive Sentiment: Market reaction was strong: shares surged on the buyout news and there was a large uptick in call-option activity (20,759 calls traded, ~519% above average), consistent with heavy bullish positioning around the deal. Read More.
• Positive Sentiment: Analyst commentary highlighting Day One’s commercial momentum (OJEMDA growth) and upcoming clinical milestones remains supportive of intrinsic value beyond the deal price, which could influence investor sentiment on alternative bidders or negotiations. Read More.
• Neutral Sentiment: Trading was temporarily halted ahead of the announcement for “news pending,” a routine market-protection measure that preceded the deal release.
• Neutral Sentiment: Needham reaffirmed a “hold” rating on the stock — a reminder some analysts still see limited upside versus the deal price absent alternate bidders or a higher offer. Read More.
• Negative Sentiment: Multiple law firms (Ademi LLP, Halper Sadeh LLC, Monteverde & Associates) have launched investigations and potential class-action claims alleging the buyout may not provide a fair price, which could lead to litigation, delay closing or pressure terms. Read More. Read More. Read More.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.